Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma - Summary - MDSpire
Advertisement
Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma
To determine the incidence and timing of hypopituitarism and other endocrinopathies in patients receiving ipilimumab and nivolumab for metastatic melanoma.
Key Findings:
Endocrinopathy was detected in 44.1% of patients, with 18.7% having hypopituitarism and 25.4% with primary hypothyroidism.
The median time to onset for hypopituitarism was 72.5 days and for hypothyroidism was 58 days.
Endocrinopathy development correlated with improved clinical outcomes.
Prompt endocrine replacement therapy was initiated for all affected patients.
Interpretation:
Routine monitoring for hypopituitarism and thyroid function is crucial in patients undergoing combination immunotherapy, given the high incidence of endocrinopathy.
Limitations:
The study was retrospective and limited to a single physician's patient cohort.
Potential biases in patient selection and data reporting may exist.
Conclusion:
Routine endocrine monitoring is strongly recommended for patients receiving ipilimumab and nivolumab due to the high rates of hypopituitarism and other endocrinopathies.
Eleanor Fallon, MD, joined Roswell Park Comprehensive Cancer Center to combine her two passions: treating melanoma and non-melanoma skin cancers and research into how immunotherapy can be used to make other therapies more effective.
